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Abstract
Intravenous immunoglobulin (IVIG) is the first line treatment for Guillain–Barre´ syndrome and multifocal motor neuropathy,
which are caused by anti-ganglioside antibody-mediated complement-dependent cytotoxicity. IVIG has many potential
mechanisms of action, and sialylation of the IgG Fc portion reportedly has an anti-inflammatory effect in antibody-
dependent cell-mediated cytotoxicity models. We investigated the effects of different IVIG glycoforms on the inhibition of
antibody-mediated complement-dependent cytotoxicity. Deglycosylated, degalactosylated, galactosylated and sialylated
IgG were prepared from IVIG following treatment with glycosidases and glycosyltransferases. Sera from patients with
Guillain–Barre´ syndrome, Miller Fisher syndrome and multifocal motor neuropathy associated with anti-ganglioside
antibodies were used. Inhibition of complement deposition subsequent to IgG or IgM autoantibody binding to ganglioside,
GM1 or GQ1b was assessed on microtiter plates. Sialylated and galactosylated IVIGs more effectively inhibited C3 deposition
than original IVIG or enzyme-treated IVIGs (agalactosylated and deglycosylated IVIGs). Therefore, sialylated and
galactosylated IVIGs may be more effective than conventional IVIG in the treatment of complement-dependent
autoimmune diseases.
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Introduction
Intravenous immunoglobulin (IVIG) is a therapeutic prepara-
tion of concentrated normal human polyclonal IgG obtained from
plasma of several thousands of healthy donors. IVIG is widely used
in the treatment of autoimmune and inflammatory diseases
including immune-mediated neuropathies [1]. The precise action
mechanism is not entirely well-understood. The immunosuppres-
sive function of IgG molecules in association with their glycosyl-
ation has been a particular focus of interest. The carbohydrate
moieties of human IgG determine a variety of biologic functions in
health and disease [2]. A better understanding of the biological
functions of the different IgG glycoforms may suggest ways of
enhancing the anti-inflammatory activity of IgG concentrates.
Glycosylation at both Fab and Fc portions provides a wide
heterogeneity to IgG antibodies, with the variable addition of the
bisecting N-acetylglucosamine, fucose to the core, as well as
galactose and sialic acid to the arms of the biantennary structure
(Figure 1). Glycosylation of IgG is divided into three glycoforms;
galactosylated, agalactosylated and sialylated.
Guillain–Barre´ syndrome (GBS) is the most common cause of
acute flaccid paralysis, and is divided into acute inflammatory
demyelinating polyneuropathy and acute motor axonal neuropa-
thy (AMAN) [3]. Molecular mimicry between microorganisms and
gangliosides can induce the development of anti-GM1 or anti-
GD1a IgG antibodies in patients with AMAN. The pathogenic
autoantibodies bind to GM1 and GD1a, and activate complement
at the nodes of Ranvier in the peripheral motor nerves allowing
formation of the membrane attack complex at the nodal
axolemma, resulting in muscle weakness. It is likely that other
GBS variants such as Miller Fisher syndrome (MFS), and other
immune-mediated neuropathies such as multifocal motor neurop-
athy (MMN) with conduction block, also relies on complement-
dependent cytotoxicity (CDC).
IVIG is the first line treatment of GBS and MMN [3,4]. IVIG
inhibits complement deposition mediated by anti-GM1 IgM
antibodies in MMN [5,6], and anti-ganglioside IgG antibodies in
GBS [7,8]. The different IVIG glycoforms have variable anti-
inflammatory effects. For instance, Fc portion sialic acid-enriched
IVIG increases its anti-inflammatory activities in a model of
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arthritis, which is caused by antibody-dependent cell-mediated
cytotoxicity (ADCC) [9]. The extent of the inhibitory effect
exerted by different IVIG glycoforms in autoantibody-mediated
CDC remains unresolved. In this study, we investigated four IVIG
glycoforms with the aim of determining the IVIG glycoform that
most effectively inhibit complement activation in sera from
patients with AMAN, MFS and MMN.
Materials and Methods
Blood samples
Sera from patients presenting to Dokkyo Medical University
(Tochigi, Japan) and University Malaya Medical Centre (Kuala
Lumpur, Malaysia) with AMAN associated with anti-GM1 IgG
antibodies (n = 3), MFS associated with anti-GQ1b IgG antibodies
(n = 3) and MMN associated with anti-GM1 IgM antibodies
(n = 3) were collected. Informed written consent was obtained
from each patient. Normal human sera were prepared from five
healthy subjects as a complement source. The study was approved
by the Dokkyo Medical University Ethics Committee and
University Malaya Medical Centre Medical Research Ethics
Committee.
Preparation of IgG glycoforms
For deglycosylation, polyethylene-treated IVIG (Glovenin-I;
Nihon Pharmaceutical, Tokyo, Japan) was dissolved with distilled
Figure 1. Preparation of different glycoforms of intravenous immunoglobulin (IVIG). Deglycosylated, agalactosylated, galactosylated and
sialylated forms were prepared from conventional IVIG by treatment with PNGase F, sialidase and galactosidase, galactosyltransferase, and
galactosyltransferase and sialyltransferase, respectively. Each IVIG glycoform was isolated using Protein G column. The structure of N-glycans attached
to IVIG was confirmed by high-performance liquid chromatography.
doi:10.1371/journal.pone.0107772.g001
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water and the solution (20 mg/mL) was treated with 40,000 U/
mL of PNGase F (New England BioLabs, Tokyo, Japan) for 16 hrs
at 37uC. For the removal of sialic acid residue, IVIG solution
(12 mg/mL) in 75 mM sodium acetate buffer (pH 5.5) was
incubated with 0.1 U/mL of sialidase from Arthrobacter ureafa-
ciens (Nakalai Tesque, Kyoto, Japan) for 16 hrs at 37uC. To
remove the galactose residue, 2 U/mL of b-galactosidase from
Streptococcus pneumoniae (ProZyme, Hayward, CA) was added to
the sialidase-treated IVIG solutions. These glycosidase-treated
IVIGs were purified using Affi-gel protein G column (Bio Rad,
Tokyo, Japan). The eluted fraction was immediately neutralized
using 1.5 M Tris-HCl buffer, pH 8.5. For the galactosylation
reaction, IVIG solution (12 mg/mL) in 50 mM Tris-HCl, 10 mM
MnCl2 was treated with 2 U/mL of galactosyltransferase from
bovine milk (Sigma-Aldrich, Tokyo, Japan) in the presence of
UDP-galactose for 16 hrs at 37uC. For the sialylation, galactosy-
lated IVIG (8 mg/mL) in 40 mM cacodylate (pH 6.0), 1.5 mM
MnCl2 was treated with 90 mU/mL of human a2,6-sialyltransfer-
ase (Merck, Tokyo, Japan) in the presence of 15 mM cytidine
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Figure 2. Complement deposition on ganglioside-coated
microtiter plates using anti-GM1 IgM (n=6), anti-GM1 (n=8)
or anti-GQ1b (n = 11) IgG antibodies from patients with
multifocal motor neuropathy, Guillain–Barre´ or Miller Fisher
syndrome (total 25 samples). All patients’ sera were diluted (1:100)
and complement source was diluted (1:100). C3 and C4 deposition were
measured as optical densities (OD) at 492 nm. Each sample’s C3 and C4
deposition OD were plotted and correlation coefficient was calculated
(A). Intravenous immunoglobulin (IVIG) inhibited the classical comple-
ment pathway. Patients’ serum diluted (1:100), complement source
diluted (1:100) and IVIG (10 mg/mL) or human serum albumin (HSA,
10 mg/mL; control) were treated. C3 and C4 deposition were measured
as optical densities (OD) at 492 nm. The results were normalized to the
HSA treated C3 deposition OD, and showed as % of control (B).
doi:10.1371/journal.pone.0107772.g002
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monophosphate-sialic acid, 4 mg/mL of bovine serum albumin,
0.08% (v/v) Triton X-100 and 8 U/mL of alkaline phosphatase
from calf intestine (TaKaRa-Bio, Shiga, Japan) for 3 days. During
the reaction, 15 mM cytidine monophosphate-sialic acid was
added to the reaction mixture every 12 hrs. These reaction
mixtures were applied to Affi-gel protein G column to purify the
galactosylated and sialylated IVIG. The eluted fractions were
immediately neutralized using 1.5 M Tris-HCl buffer, pH 8.5.
Figure 3. Complement deposition on ganglioside-coated microtiter plates using serum anti-GM1 or anti-GQ1b IgG antibodies from
patients with Guillain–Barre´ or Miller Fisher syndrome. Reduction of C3 deposition in the presence of constant amounts of intravenous
immunoglobulin (IVIG) (10 mg/mL) or human serum albumin (HSA, 10 mg/mL; control) and serial dilution of patients’ serum (A) or complement
source (B). C3 deposition decreased along with serial dilution of patients’ serum and complement source. Dose-dependent inhibition of C3
deposition by IVIG compared with HSA (C). F(ab’)2 did not inhibit C3 deposition whereas IVIG and the Fc portion did (1 mg/mL) (D). Antibodies once
bound to GM1 or GQ1b were not displaced by IVIG (E). Results were given as optical densities (OD) at 492 nm. The results were normalized to the
lowest concentration of HSA treated, and showed as % of control. Each experiment was performed at least 3 times for each serum sample with anti-
GM1 (n = 3) and anti-GQ1b IgG antibodies (n = 3) and representative results were shown. Experiment condition: (A) complement source (1:100); (B)
serum sample with anti-GM1 (1:200), anti-GQ1b (1:1000) IgG antibodies; (C–E) serum sample with anti-GM1 (1:200), anti-GQ1b (1:1000) IgG
antibodies, complement source (1:100).
doi:10.1371/journal.pone.0107772.g003
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The structure of N-glycans attached to IVIG was confirmed by
high performance liquid chromatography (HPLC).
Fragmentation of IgG with papain digestion
IVIG solution (5 mg/mL) was incubated with papain (Sigma-
Aldrich, Tokyo, Japan) at pH 7.0, 37uC, in 75 mM sodium
Figure 4. Complement deposition on ganglioside-coated microtiter plates using anti-GM1 IgM, anti-GM1 or anti-GQ1b IgG
antibodies from patients with multifocal motor neuropathy, Guillain–Barre´ or Miller Fisher syndrome. Dose-dependent inhibition of C3
deposition by different glycoforms of intravenous immunoglobulin (IVIG) compared to the effect of human serum albumin (HSA). HSA and the
various IVIG gylcoforms showed some dose effect on C3 deposition. When compared to the effect of HSA, galactosylated and sialylated forms at all
concentrations tested inhibited C3 deposition more effectively than conventional IVIG, whereas agalactosylated or deglycosylated forms did not have
an effect. The results were normalized to HSA treated column, and showed as % of control. Each experiment was performed for at least 3 times for
each serum sample with anti-GM1 IgM (n = 3), anti-GM1 (n = 3) and anti-GQ1b (n = 3) IgG antibodies and representative results were shown.
Experiment condition: serum sample with anti-GM1 IgM (1:2000), anti-GM1 (1:100), anti-GQ1b (1:500) IgG antibodies and complement source (1:200).
doi:10.1371/journal.pone.0107772.g004
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phosphate buffer containing 75 mM NaCl and 2 mM EDTA. The
enzyme/substrate ratio (w/w) was 1:25, and the digestion period
was 6 hrs. The reaction was terminated by addition of 33 mM N-
ethyl-maleimide. Fab and Fc fragments were separated and
purified using Affi-gel protein A column (Bio Rad, Tokyo, Japan)
and HiLoad 16/60 Superdex 200 prep grade column
(16 mm660 cm, GE Healthcare, Buckinghamshire, England).
The eluted fraction was immediately neutralized using 1.5 M
Tris-HCl buffer, pH 8.5. The purity of Fab and Fc fragments was
confirmed by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis under reducing and non-reducing conditions.
Isolation and characterization of N-glycans attached to
IgG
Release of N-glycans from IgG sample and subsequent
derivatization with 2-aminopyridine was performed using Blot-
Glyco (Sumitomo Bakelite, Tokyo, Japan) under the manufactur-
er’s instruction with slight modifications. The released N-glycans
and peptides were removed using a graphite carbon column
(InertSep GC, GL Sciences, Tokyo, Japan), and free 2-aminopyr-
idine was removed from the reaction mixture using MonoFas I
Spin Column (GL Sciences, Tokyo, Japan). The resultant
pyridylamino (PA)-glycans were then applied on a LaChrom Elite
HPLC system (Hitachi, Tokyo, Japan) under conditions reported
previously [10,11] using a TSKgel DEAE-5PW (7.5 mm67.5 cm,
Tosoh Corporation, Tokyo, Japan) and a Shim-pack HRC-ODS
column (6.0 mm615 cm, Shimadzu, Kyoto, Japan). PA-oligosac-
charides were detected by fluorescence using excitation and
emission at 320 and 400 nm, respectively. Elution times of the
individual peaks from the ODS columns were normalized with
respect to the PA-derivatized isomalto oligosaccharides with
degree of polymerization 3–22 (TaKaRa-Bio, Shiga, Japan), and
reported in glucose units (GU). PA-oligosaccharides derived from
IVIG were identified by comparison with the GUs of reference
PA-oligosaccharides in a web application, GALAXY (http://
www.glycoanalysis.info/) [12]. The amount of PA-oligosaccha-
rides was estimated using the peak area in the chromatogram.
Complement deposition assays inhibited by different
IVIG glycoforms
The assays were performed as described elsewhere with a minor
modification [5]. Phosphate-buffered saline containing 2% casein
sodium salt was used for each dilution. Diluted sera from patients
with anti-GM1 or anti-GQ1b antibodies were added to ganglio-
side-coated plates. Each ganglioside was purified from bovine
brain ganglioside mixture by Q-Sepharose (Pharmacia, Uppsala,
Sweden) column chromatography. After washing with phosphate-
buffered saline containing 0.05% Tween 20, normal human sera
were added as a source of complement. To detect complement
deposition, peroxidase-conjugated anti-human C3 antibodies (MP
Biomedicals LLC, Solon, OH), anti-human C4 antibodies
(CEDARLANE Laboratories, Ontario, Canada) and anti-chicken
IgY (IgG) (whole molecule) peroxidase, antibody produced in
rabbit (Sigma-Aldrich, Singapore) were used. To identify the
region of IgG that can inhibit complement deposition, F(ab’)2
KAKETSUKEN (KAKETSUKEN, Kumamoto, Japan) and
human IgG-Fc (BETHYL Laboratories, Montgomery, TX) were
used. The experiments were performed in quadruples.
In the second part of the experiment, we investigated whether
IVIG (Glovenin-I) and different IVIG glycoforms can inhibit
complement deposition mediated by anti-GM1 and anti-GQ1b
antibodies. To remove non-specific binding and to ensure there
was persistent binding of pathogenic immunoglobulin to the
immune complex, the plates were washed and exposed to 50 ml of
diluted normal human sera mixed with an equal volume of
different glycoforms at 0.25–1 mg/mL. The plates were then
incubated at 37uC for 1 hr. As control, preformed immune
complexes were incubated with a solution of 0.25–1 mg/mL of
human serum albumin. Following addition of anti-human C3
antibodies as per standard protocol, optical densities were read
using a microplate reader (Multiskan GO; Thermo Fisher
Scientific).
Results and Discussion
Structural analysis of N-glycans attached to IgG
We first examined the N-glycan structure attached to original
IVIG and its fragment (Fab and Fc). The N-glycans were released
using PNGase F, derivatized with 2-aminopyridine and charac-
terized by HPLC method. The results are summarized in Table1.
The original IVIG contains agalactosylated (G0 form, 27%),
monogalactosylated (G1 form, 37%), digalactosylated (G2 form,
19%), monosialylated (S1 form, 14%), and disialylated (S2 form,
3%) N-glycans. Fc fragment from original IVIG contains
agalactosylated (G0 form, 24%), monogalactosylated (G1 form,
42%), digalactosylated (G2 form, 22%), and monosialylated (S1
form, 11%) N-glycans. In contrast, Fab fragment contains
matured N-glycans, agalactosylated (G0 form, 4%), monogalacto-
sylated (G1 form, 10%), digalactosylated (G2 form, 8%),
monosialylated (S1 form, 40%), and disialylated (S2 form, 38%)
N-glycans. The result is mostly consistent with the previous glycan
analyses on human serum IgG and its fragments [13]. The amount
of N-glycans attached to Fab was estimated as 0.1 mol/mol Fab.
By galactosidase or galactosyltransferase treatment of IVIG,
agalactosylated form (G0 form, 100%) or galactosylated form (G2
form, 84%) was obtained. N-glycans from galactosyltransferase
and sialyltransferase-treated IVIG showed disialylated form (S2
form, 15%), monosialylated form (S1 form, 81%) and asialo form
(G2 form, 4%). N-glycans were essentially not detected from
PNGase F-treated IVIG, confirming the almost complete
deglycosylation by that enzyme.
Inhibition of activated complement deposition by IVIG
Previous studies have demonstrated that IVIG can inhibit
complement deposition mediated by anti-GM1 IgM antibodies
from patients with MMN [5,6]. In this study, we demonstrate that
IVIG also inhibits complement deposition mediated by anti-GM1
and anti-GQ1b IgG antibodies from patients with AMAN and
MFS respectively. Deposition of C1q, the first complement
reacting with immune complexes, and of C4, another component
of the classical complement pathway, as well as deposition of C3
were highly correlated to anti-ganglioside antibody titers [5]. The
strong correlation of classical complement pathway components
C3 and C4 (r = 0.92) suggests that IVIG has a role in inhibiting the
classical complement pathway (Figure 2A, B). Subsequent
experiments were focused on C3 deposition as follows. The extent
of IVIG-mediated blocking of complement deposition in vitro
varied based on three parameters: (i) autoantibody dose, (ii)
complement dose, and (iii) IVIG dose. C3 deposition was reduced
with higher dilution of patients’ sera and complement source
(Figure 3A, B). IVIG dose-dependently reduced C3 deposition;
whereas, human serum albumin had no effect on complement
deposition (Figures 3C and S1). Similar to human serum
albumin, F(ab’)2 did not show C3 deposition inhibitory effects,
while Fc portion inhibited C3 deposition similar to IVIG,
suggesting that the Fc portion is the key component in the
inhibition of activated complement deposition (Figure 3D).
Effect of IVIG Glycoforms on Complement Deposition
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In a previous study, IVIG was reported to displace anti-GQ1b
antibodies after its binding to the GQ1b antigen [7]. We
investigated this further in vitro by adding IVIG to patients’ sera
that were incubated and reacted to the corresponding ganglioside.
We found that IVIG did not displace anti-ganglioside IgG or IgM
antibodies bound to GM1 or GQ1b in our assays (Figure 3E).
Thus, it is likely that IVIG acts by inhibiting complement
deposition and not by altering the pathogenic antibody content in
immune complexes.
We demonstrate representative data from the analyses of three
independent patient sera samples. The autoantibody titers in each
patient sera sample were different and thus, a statistical
comparison could not be made. However, the reactivity patterns
seen were similar to representative reactions.
The effect of IVIG glycosylation on inhibition of
complement deposition
Since 2001, the role of IgG sialylation in the therapeutic effects
of IVIG has been studied in animal models [14]. IgG enriched in
terminal sialic acid content has been considered to account for the
anti-inflammatory effect of IVIG. However, this hypothesis has
since been challenged [15]. More importantly, there is a paucity of
data that validates the findings of animal experiments in humans.
In the current study, we aimed to explore the anti-inflammatory
role of IgG glycosylation, in particular for that of terminal sialic
acid in human disease. We selected human inflammatory
peripheral neuropathies as our model because CDC has been
reported in their pathogenesis. Our in vitro system, with the
exception of the purified ganglioside antigens, was purely of
human origin.
In this study, we demonstrated that different IVIG glycoforms
affect the inhibition of complement deposition mediated by
autoantibodies. Different glycoforms of IVIG were prepared from
conventional IVIG as previously described (Figure 1). The extent
of C3 deposition by different glycoforms of IVIG was dose-
dependent. Sialylated and galactosylated IVIGs inhibited C3
deposition more effectively than conventional IVIG. In contrast,
neither agalactosylated nor deglycosylated IVIG appeared to
inhibit C3 deposition. This result was reproducible irrespective of
the pathological autoantibodies isotype, i.e. IgG or IgM. There
was a 2- to 4-fold increase in inhibitory effect of sialylated and
galactosylated IVIGs compared to agalactosylated and deglycosy-
lated IVIGs (Figures 4 and S2). Sialylated IVIG led to more than
a 10-fold increase of anti-inflammatory activity in an ADCC
model, whereas the removal of sialic acid from the preparation
abolished its therapeutic efficacy [9]. Galactosylated and sialylated
IVIG may be more effective in the treatment of autoimmune
disorders.
Conclusion
In the current study, we investigated the effects of IVIG
glycosylation on the inhibition of complement deposition. To the
best of our knowledge, this is the first study which demonstrates
in vitro that different glycoforms of IgG can affect the extent of
inhibition of complement deposition mediated by pathological
autoantibodies. In our in vitro anti-ganglioside antibody mediated
complement deposition assay system, IVIG-mediated blocking of
complement deposition was due to the Fc portion and the
galactosylation and sialylation of Fc region enhanced blocking of
complement deposition. With the advent of Fc glycoengineering,
we expect to unravel the underlying therapeutic mechanisms of
IVIG, resulting in more effective immunotherapy.
Supporting Information
Figure S1 Complement deposition on ganglioside-coat-
ed microtiter plates using anti-GM1 IgM, anti-GM1 or
anti-GQ1b IgG antibodies from patients with multifocal
motor neuropathy, Guillain–Barre´ or Miller Fisher
syndrome. Dose-dependent inhibition of C3 deposition by
intravenous immunoglobulin (IVIG) compared to the effect of
human serum albumin (HSA). Results were given as optical
densities (OD) at 492 nm. The results were normalized to the
lowest concentration of HSA treated, and showed as % of control.
Experiment condition: serum sample with anti-GM1 IgM
antibodies (1:2000, left side), (1:500, right side); anti-GM1 IgG
antibodies (1:500, left side), (1:200, right side); anti-GQ1b IgG
antibodies (1:1000, left side), (1:500, right side) and complement
source (1:100).
(DOCX)
Figure S2 Complement deposition on ganglioside-coat-
ed microtiter plates using anti-GM1 IgM, anti-GM1 or
anti-GQ1b IgG antibodies from patients with multifocal
motor neuropathy, Guillain–Barre´ or Miller Fisher
syndrome. Dose-dependent inhibition of C3 deposition by
different glycoforms of intravenous immunoglobulin (IVIG)
compared to the effect of human serum albumin (HSA). HSA
and the various IVIG gylcoforms showed some dose effect on C3
deposition. When compared to the effect of HSA, galactosylated
and sialylated forms at all concentrations tested inhibited C3
deposition more effectively than conventional IVIG, whereas
agalactosylated or deglycosylated forms did not have an effect.
The results were normalized to HSA treated column, and showed
as % of control. Each experiment was performed for at least 3
times for each serum sample with anti-GM1 IgM (n=3), anti-
GM1 (n= 3) and anti-GQ1b (n= 3) IgG antibodies and represen-
tative results were shown. Experiment condition: serum sample
with anti-GM1 IgM (1:1000), anti-GM1 (1:500), anti-GQ1b
(1:500) IgG antibodies and complement source (1:200).
(DOCX)
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